Get the Stockscreener App
0.6706
0.80%
-0.0054
Tenaya Therapeutics Inc stock is traded at $0.6706, with a volume of 1.57M.
It is down -0.80% in the last 24 hours and up +11.21% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$0.676
Open:
$0.69
24h Volume:
1.57M
Relative Volume:
0.64
Market Cap:
$109.08M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.508
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
-19.52%
1M Performance:
+11.21%
6M Performance:
-36.74%
1Y Performance:
-78.95%
1-Day Range:
$0.6441
$0.69
1-Week Range:
$0.6441
$0.8332
52-Week Range:
$0.36
$4.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6706 | 109.96M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
How sentiment analysis helps forecast Tenaya Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
Is Tenaya Therapeutics Inc. stock bottoming outVolume Confirmed Setup with Entry Confidence - Newser
How to read the order book for Tenaya Therapeutics Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Can Tenaya Therapeutics Inc. hit a new high this monthFree Fundamental Growth Stock Analysis - Newser
Advanced analytics toolkit walkthrough for Tenaya Therapeutics Inc.Technical Confirmation System with Signal Alerts - Newser
How does Tenaya Therapeutics Inc. generate profit in a changing economyChart Pattern Strategy To Watch Now - jammulinksnews.com
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of “Buy” from Analysts - Defense World
Why is Tenaya Therapeutics Inc. stock attracting strong analyst attentionEntry Signal Alerts With Low Risk - jammulinksnews.com
Using economic indicators to assess Tenaya Therapeutics Inc. potentialReal Market Tracker with Price Action Tools - Newser
Will Tenaya Therapeutics Inc. stock go up soonFundamental Forecast for Undervalued Stocks - Newser
What institutions are buying Tenaya Therapeutics Inc. stock nowFundamental Forecast for Undervalued Stocks - Newser
Intrinsic Value of Tenaya Therapeutics Inc. Stock: Is It Undervalued or OvervaluedDaily Breakout List with Smart Filters - Newser
Does Tenaya Therapeutics Inc. stock perform well during market downturnsStock Market Entry Points To Watch Now - jammulinksnews.com
Published on: 2025-07-30 22:05:21 - metal.it
Tenaya Receives Positive Safety Reviews from Independent - GlobeNewswire
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies By Investing.com - Investing.com South Africa
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies - Investing.com
Gene Therapy's Cardiovascular Revolution: Why Tenaya Therapeutics Is a High-Conviction Bet in 2025 - AInvest
Tenaya completes enrollment in both dose cohorts for HCM gene therapy - Investing.com
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed - The Manila Times
Breakthrough: Tenaya's Dual Heart Disease Gene Therapies Pass Major Safety Milestone - Stock Titan
How Resilient Is Tenaya Therapeutics Inc. Stock During Economic DownturnsEarly Buy Opportunity with Chart Triggers - Newser
Will earnings trigger a reversal in Tenaya Therapeutics Inc.Real-Time AI Entry Forecast Generator - Newser
What analysts say about Tenaya Therapeutics Inc. stock outlookEntry Optimization Tool with Screener Logic - Newser
Analyzing net buyer seller activity in Tenaya Therapeutics Inc.Free Reversal Alert Based on RSI Indicator - Newser
What are the latest earnings results for Tenaya Therapeutics Inc.Achieve superior returns through strategic trading - jammulinksnews.com
Is it the right time to buy Tenaya Therapeutics Inc. stockEarnings Report Insights With Low Risk - jammulinksnews.com
How Tenaya Therapeutics Inc. stock performs during market volatilityFree AI Screening for Swing Trade Picks - Newser
Is Tenaya Therapeutics Inc. forming a reversal patternInvestment Life Cycle Planning Summary - Newser
What is the dividend policy of Tenaya Therapeutics Inc. stockSuperior profit margins - jammulinksnews.com
What makes Tenaya Therapeutics Inc. stock price move sharplyAchieve triple-digit returns with smart investing - jammulinksnews.com
What is Tenaya Therapeutics Inc. company’s growth strategyDiscover market opportunities with real-time data - jammulinksnews.com
Why Tenaya Therapeutics Inc. stock attracts strong analyst attentionAI Powered Stock Call - Newser
Is Tenaya Therapeutics Inc. a Top Dividend Stock to Watch in 2025Consistent Win Signals - Newser
Is Tenaya Therapeutics Inc. stock a growth or value playFree Investment Risk Control - jammulinksnews.com
What analysts say about Tenaya Therapeutics Inc. stockAccelerated investment success - PrintWeekIndia
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):